FuturedMe
Japan · Biotech
FuturedMe develops small-molecule drug discovery technology that directs disease-related proteins to the cell’s natural degradation machinery.
Product
FuturedMe develops drug candidates for diseases whose underlying proteins are difficult to address with conventional medicines. Its CANDDY platform uses small molecules to direct selected proteins to the proteasome, the cell’s natural protein-degradation machinery. The approach works without the ubiquitination step used by several other targeted-degradation technologies.
The company applies this platform to research on targets associated with cancer and autoimmune disease, combining compound design with biological evaluation. FuturedMe grew out of research at Tokyo University of Science and was founded in June 2018. Its headquarters are in Tokyo, with research facilities in Kashiwa.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Equity financing | ¥150M | Real Tech Fund IV Investment Limited Partnership — Lead |